Yes. In our interconnected world, where diseases and health issues transcend borders, and where the most challenging health problems cannot be solved by any one country, it is essential for nations to work together to improve healthcare and promote global well-being. ARPA-H recognizes the importance of international cooperation and coordination, and will continue to explore opportunities to do so.
While ARPA-H will prioritize awards to entities (organization or individuals) that will conduct funded work in the United States, it is not a requirement. For clinical trials, ARPA-H strongly prefers that they be performed in the United States. However, trials in other countries will be considered on a case-by-case basis at ARPA-H's discretion.
Yes, ARPA-H can contract with a foreign entity. Pursuant to 42 U.S.C. 290c(n)(1), ARPA-H will prioritize awards to entities (organization and/or individuals) that will conduct funded work in the United States. However, non-U.S. entities may participate to the extent that such participants comply with any necessary nondisclosure agreements, security regulations, export control laws, and other governing statutes applicable under the circumstances. Non-U.S. entities are encouraged to collaborate with domestic U.S. entities. In no case will awards be made to entities organized under the laws of a covered foreign country [as defined in section 119C of the National Security Act of 1947 (50 U.S.C. § 3059)] or entities suspended or debarred from business with the U.S. Government.
In reviewing foreign applications, ARPA-H relies on the Foreign Award and Component Tracking System (FACTS) process established by the National Institutes of Health (NIH), which sends a request to the Department of State, including U.S. embassies, to review foreign components—i.e., the performance of any significant scientific elements of a project involving sites, researchers, collaborators, collaborating organizations, and/or institutes outside the U.S. More information is available at the NIH’s FACTS website.
The Division of International Affairs at ARPA-H is responsible for promoting and managing international collaborations, partnerships, and initiatives that advance the agency's mission of driving innovation in biomedical research. The Division of International Affairs formulates and executes ARPA-H's global collaboration strategy by identifying key international stakeholders, potential partners, and research opportunities that align with the agency's mission and enhance the impact of ARPA-H's initiatives on a global scale.
Eligibility criteria for international funding opportunities vary. ARPA-H welcomes applications from qualified international researchers, institutions, and organizations. Specific eligibility criteria, including qualifications and project scopes, are detailed in the guidelines accompanying each program solicitation on SAM.gov. In general, like U.S. participants, international partners can participate in ARPA-H research contracts as either a “prime organization” or on a team as a “subcontractor.” Interested international partners may sign up on “teaming” pages on our website – linked from each program description page – which are provided to facilitate teaming.
International partnerships, like domestic partnerships, should advance the goals of ARPA-H programs and other funding opportunities. ARPA-H continues to solicit innovative proposals for health and health care research and development (R&D) across its four missions areas: Health Science Futures, Resilient Systems, Scalable Solutions, and Proactive Health.